🚀 Most Anticipated IPO of the Decade
SpaceX IPO — June 11, 2026
S-1 filed May 22. Roadshow begins June 8. Pricing June 11. NYSE: SPCE2 (proposed)
16Days
08Hours
24Minutes
11Seconds
This Week May 26 - May 30
Monday
May 26
CPI/Jobs ECON
8:30 AM ET
RGTI E
After Close
Tuesday
May 27
Consumer Conf ECON
10:00 AM ET
ONON E
Before Open
Wednesday
May 28
FOMC Minutes ECON
2:00 PM ET
NVDA ⚡ HOT
After Close
Thursday
May 29
GDP Revision ECON
8:30 AM ET
PCE Deflator ECON
8:30 AM ET
COST E
After Close
Friday
May 30
Core PCE 🔴 KEY
8:30 AM ET — Fed preferred
Chicago PMI ECON
9:45 AM ET
Upcoming PDUFA Dates Biotech Binary Events
SMMT
Summit Therapeutics
PDUFA
June 12, 2026 — 16 days
FDA decision on ivonescimab for NSCLC (non-small cell lung cancer). Phase 3 HARMONi-2 showed superiority over Keytruda in Chinese patients. FDA evaluating whether US trial required for approval. Binary event.
Drug
Ivonescimab
Peak Sales Est
$8.2B
VKTX
Viking Therapeutics
PDUFA
July 26, 2026 — 60 days
FDA decision on VK2809 for NASH (liver disease). Phase 2b data showed significant liver fat reduction. Competing in a $35B+ market against Madrigal and Novo Nordisk. Approval would be transformational for the company.
Drug
VK2809
Market Size
$35B+
This Week Earnings 3 Key Reports
NVDA
Nvidia Corporation
⚡ HOT
Wednesday May 28 — After Close
Q1 FY2027 earnings. The most important print of the week. AI infrastructure demand remains the key driver. Data center segment expected to account for $84B of total revenue. Watch China revenue guidance — any upside there is a significant positive surprise.
Rev Estimate
$91.5B
EPS Estimate
$0.87
Implied Move
±10%
IV Rank
84
ONON
On Holding AG
EARNINGS
Tuesday May 27 — Before Open
Q1 2026 earnings. Swiss running shoe brand with strong momentum in the premium athletic segment. Key metrics: revenue growth rate (consensus +28% YoY), gross margin trajectory, and North America market share commentary. Recent insider buy of $6.6M is a bullish signal heading in.
Rev Estimate
$2.84B
EPS Estimate
$0.21
Implied Move
±7%
IV Rank
58
COST
Costco Wholesale
EARNINGS
Thursday May 29 — After Close
Q3 FY2026 earnings. Costco is a bellwether for consumer health. Membership fee renewal rates and comp sales growth are the key metrics. Tariff commentary will be watched closely given Costco's heavy import exposure.
Rev Estimate
$62.4B
EPS Estimate
$4.14
Implied Move
±4%
IV Rank
32
Earnings History — Recent Beats and Misses
| Ticker | Date | Rev Actual | Rev Est | EPS Actual | EPS Est | Result | Reaction |
|---|---|---|---|---|---|---|---|
| IONQ | May 8 | $12.4M | $11.8M | -$0.18 | -$0.22 | BEAT | +13.4% |
| NVDA | Feb 26 | $39.3B | $38.0B | $0.89 | $0.84 | BEAT+RAISE | +4.2% |
| HIVE | May 14 | $42.8M | $39.1M | $0.04 | $0.02 | BEAT | +8.6% |
| ONON | May 6 (prev) | $2.65B | $2.55B | $0.19 | $0.17 | BEAT | +6.8% |
| SMMT | Apr 22 | $18.2M | $15.4M | -$0.42 | -$0.48 | BEAT | +3.2% |
🚀 IPO Countdown
SpaceX — NYSE: SPCE2
The largest IPO in history by market cap. Roadshow June 8-10. Pricing June 11. Trading begins June 12.
16Days
08Hours
24Minutes
11Seconds
IPO Pipeline 2026
| Company | Ticker | Sector | Est. Valuation | Expected Date | Status | PDB Play |
|---|---|---|---|---|---|---|
| SpaceX | SPCE2 | Space / Defense | $1.75T | June 11, 2026 | ROADSHOW | DXYZ, RKLB, RDW |
| Stripe | STRP | Fintech | $90B | Q3 2026 | FILED S-1 | Fintech ETF |
| Databricks | DBX2 | AI / Data | $62B | Q4 2026 | RUMORED | AI ETFs |
| Klarna | KLAR | BNPL / Fintech | $15B | Q3 2026 | FILED S-1 | Direct play |
| xAI (Grok) | XAI | AI / Tech | $50B | 2027 (TBD) | SPECULATIVE | X Corp exposure |
What is a PDUFA date? The Prescription Drug User Fee Act (PDUFA) date is the FDA deadline to approve or reject a new drug application. These are binary events — approval can double a stock, rejection can cut it in half. Our FDA scanner bot monitors these in real time.
Upcoming PDUFA Dates Next 90 Days
| Ticker | Company | Drug | Indication | PDUFA Date | Days | Consensus | Est. Move |
|---|---|---|---|---|---|---|---|
| SMMT | Summit Therapeutics | Ivonescimab | NSCLC 1L | Jun 12 | 16d | LIKELY APPROVE | ±60% |
| VKTX | Viking Therapeutics | VK2809 | NASH | Jul 26 | 60d | MIXED | ±45% |
| MRNA | Moderna | mRNA-4157 | Melanoma adjuvant | Aug 4 | 69d | LIKELY APPROVE | ±25% |
| RGEN | Repligen Corp | RGN-259 | Dry Eye Disease | Aug 18 | 83d | UNCERTAIN | ±35% |